Wei Dong Gao

Dr. Wei Dong Gao

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in European Journal of Pharmacology
Verified
Journal Article
Closed access
TDTieying Dai
Tieying Dai
GRGenaro Ramirez-Correa
Genaro Ramirez-Correa
WGWei Dong Gao
Wei Dong Gao

28 September 2012 in Circulation Research
Verified
Journal Article
Closed access
PDF file
WGWei Dong Gao
Wei Dong Gao
CMChristopher I. Murray
Christopher I. Murray
YTYe Tian
Ye Tian
XZXin Zhong
Xin Zhong
JDJenna F. DuMond
Jenna F. DuMond
NPNazareno Paolocci
Nazareno Paolocci
Rationale:: In the myocardium, redox/cysteine modification of proteins regulating Ca 2+ cycling can affect contraction and may have therapeutic value. Nitroxyl (HNO), the one-electron-reduced form of nitric oxide, enhances cardiac function in a manner that suggests reversible cysteine modifications of the contractile machinery. Objective:: To determine the effects of HNO modification in cardiac myofilament proteins. Methods and Results:: The HNO-donor, 1-nitrosocyclohexyl acetate, was found to act directly on the myofilament proteins, increasing maximum force (F max ) and reducing the concentration of Ca 2+ for 50% activation (Ca 50 ) in intact and skinned cardiac muscles. The effects of 1-nitrosocyclohexyl acetate are reversible by reducing agents and distinct from those of another HNO donor, Angeli salt, which was previously reported to increase F max without affecting Ca50. Using a new mass spectrometry capture technique based on the biotin switch assay, we identified and characterized the formation by HNO of a disulfide-linked actin–tropomyosin and myosin heavy chain–myosin light chain 1. Comparison of the 1-nitrosocyclohexyl acetate and Angeli salt effects with the modifications induced by each donor indicated the actin–tropomyosin and myosin heavy chain–myosin light chain 1 interactions independently correlated with increased Ca 2+ sensitivity and force generation, respectively. Conclusions:: HNO exerts a direct effect on cardiac myofilament proteins increasing myofilament Ca 2+ responsiveness by promoting disulfide bond formation between critical cysteine residues. These findings indicate a novel, redox-based modulation of the contractile apparatus, which positively impacts myocardial function, providing further mechanistic insight for HNO as a therapeutic agent.

16 April 2007 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
TDTieying Dai
Tieying Dai
YTYe Tian
Ye Tian
Carlo Gabriele TocchettiCarlo Gabriele Tocchetti
Carlo Gabriele Tocchetti
TKTatsuo Katori
Tatsuo Katori
AMAnne M. Murphy
Anne M. Murphy
WGWei Dong Gao
Wei Dong Gao
Donors of nitroxyl (HNO), the reduced congener of nitric oxide (NO), exert positive cardiac inotropy/lusitropyin vivoandin vitro, due in part to their enhancement of Ca2+cycling into and out of the sarcoplasmic reticulum. Here we tested whether the cardiac action of HNO further involves changes in myofilament–calcium interaction. Intact rat trabeculae from the right ventricle were mounted between a force transducer and a motor arm, superfused with Krebs–Henseleit (K‐H) solution (pH 7.4, room temperature) and loaded iontophoretically with fura‐2 to determine [Ca2+]i. Sarcomere length was set at 2.2–2.3 μm. HNO donated by Angeli's salt (AS; Na2N2O3) dose‐dependently increased both twitch force and [Ca2+]itransients (from 50 to 1000 μm). Force increased more than [Ca2+]itransients, especially at higher doses (332 ± 33%versus221 ± 27%,P< 0.01 at 1000 μm). AS/HNO (250 μm) increased developed force without changing Ca2+transients at any given [Ca2+]o(0.5–2.0 mm). During steady‐state activation, AS/HNO (250 μm) increased maximal Ca2+‐activated force (Fmax, 106.8 ± 4.3versus86.7 ± 4.2 mN mm−2,n= 7–8,P< 0.01) without affecting Ca2+required for 50% activation (Ca50, 0.44 ± 0.04versus0.52 ± 0.04 μm, not significant) or the Hill coefficient (4.75 ± 0.67versus5.02 ± 1.1, not significant). AS/HNO did not alter myofibrillar Mg‐ATPase activity, supporting an effect on the myofilaments themselves. The thiol reducing agent dithiothreitol (DTT, 5.0 mm) both prevented and reversed HNO action, confirming AS/HNO redox sensitivity. Lastly, NO (from DEA/NO) did not mimic AS/HNO cardiac effects. Thus, in addition to reported changes in Ca2+cycling, HNO also acts as a cardiac Ca2+sensitizer, augmenting maximal force without altering actomyosin ATPase activity. This is likely to be due to modulation of myofilament proteins that harbour reactive thiolate groups that are targets of HNO.

1 July 2019 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
XRXianfeng Ren
Xianfeng Ren
RJRoger A. Johns
Roger A. Johns
WGWei Dong Gao
Wei Dong Gao
Right ventricular (RV) failure (RVF) has garnered significant attention in recent years because of its negative impact on clinical outcomes in patients with pulmonary hypertension (PH). PH triggers a series of events, including activation of several signaling pathways that regulate cell growth, metabolism, extracellular matrix remodeling, and energy production. These processes render the RV adaptive to PH. However, RVF develops when PH persists, accompanied by RV ischemia, alterations in substrate and mitochondrial energy metabolism, increased free oxygen radicals, increased cell loss, downregulation of adrenergic receptors, increased inflammation and fibrosis, and pathologic microRNAs. Diastolic dysfunction is also an integral part of RVF. Emerging non‐invasive technologies such as molecular or metallic imaging, cardiac MRI, and ultrafast Doppler coronary flow mapping will be valuable tools to monitor RVF, especially the transition to RVF. Most PH therapies cannot treat RVF once it has occurred. A variety of therapies are available to treat acute and chronic RVF, but they are mainly supportive, and no effective therapy directly targets the failing RV. Therapies that target cell growth, cellular metabolism, oxidative stress, and myocyte regeneration are being tested preclinically. Future research should include establishing novel RVF models based on existing models, increasing use of human samples, creating human stem cell‐based in vitro models, and characterizing alterations in cardiac excitation–contraction coupling during transition from adaptive RV to RVF. More successful strategies to manage RVF will likely be developed as we learn more about the transition from adaptive remodeling to maladaptive RVF in the future.

1 February 2018 in Journal of Cardiothoracic and Vascular Anesthesia
Verified
Journal Article
Closed access
XRXianfeng Ren
Xianfeng Ren
NHNadia Hensley
Nadia Hensley
MBMary Beth Brady
Mary Beth Brady
WGWei Dong Gao
Wei Dong Gao

11 May 2016 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TMTao Meng
Tao Meng
WBWeiming Bu
Weiming Bu
XRXianfeng Ren
Xianfeng Ren
XCXinzhong Chen
Xinzhong Chen
JYJingui Yu
Jingui Yu
WGWei Dong Gao
Wei Dong Gao
Isoflurane and propofol are known to depress cardiac contraction, but the molecular mechanisms involved are not known. In this study, we determined whether decreasing myofilament Ca 2+ responsiveness underlies anesthesia‐induced depression of contraction and uncovered the molecular targets of isoflurane and propofol. Force and intracellular Ca 2+ ([Ca 2+ ] i ) were measured in rat trabeculae superfused with Krebs‐Henseleit solution, with or without propofol or isoflurane. Photoaffinity labeling of myofilament proteins with meta‐Azi‐propofol (AziP m ) and Azi‐isoflurane (Azi‐iso) and molecular docking were also used. Both propofol and isoflurane dose dependently depressed force from low doses (propofol, 27 ± 6 μM; isoflurane, 1.0 ± 0.1%) to moderate doses (propofol, 87 ± 4 μM; isoflurane, 3.0 ± 0.25%), without significant alteration [Ca 2 +] i . During steady‐state activations in both intact and skinned preparations, propofol and isoflurane depressed maximum Ca 2+ ‐activated force and increased the [Ca 2+ ]i required for 50% of activation. Myofibrils photolabeled with AziP m and Azi‐iso identified myosin, actin, and myosin light chain as targets of the anesthetics. Several adducted residues in those proteins were located in con‐formationally sensitive regions that underlie contractile function. Thus, propofol and isoflurane decrease force development by directly depressing myofilament Ca 2+ responsiveness and have binding sites in key regions for contraction in both actin and myosin.—Meng, T., Bu, W., Ren, X., Chen, X., Yu, J., Eckenhoff, R. G., Gao, W. D. Molecular mechanism of anesthetic‐induced depression of myocardial contraction. FASEB J. 30, 2915‐2925 (2016). www.fasebj.org